DOCSLIB.ORG

ANNUAL REPORT 2018 … Is at the Heart of Every- Thing We Do

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ANNUAL REPORT 2018 … Is at the Heart of Every- Thing We Do Science ANNUAL REPORT 2018 … is at the heart of every- thing we do. € 2.2 BILLION invested in research and development in 2018. Around 52,000 hearts at Merck beat for science. Employees in 66 countries share a passion for pushing boundaries and making new discoveries. Since 1668, the name Merck has stood for the positive power of science. Online You can find out what else makes our research hearts beat faster at www.merckgroup.com/en/ annualreport/2018 “ We believe that scientific exploration and responsible entrepreneurship make techno- logical advantages possible that benefit us all.” STEFAN OSCHMANN Chairman of the Executive Board and CEO Key Figures for 2018 MERCK GROUP Key figures 1 Change € million 2018 2017 € million in % Net sales 14,836 14,517 319 2.2% Operating result (EBIT)2 1,727 2,423 – 696 – 28.7% Margin (% of net sales)2 11.6% 16.7% EBITDA2 3,528 4,164 – 636 – 15.3% Margin (% of net sales)2 23.8% 28.7% EBITDA pre2 3,800 4,246 – 446 – 10.5% Margin (% of net sales)2 25.6% 29.3% Profit after tax 3,396 2,615 781 29.9% Earnings per share (€) 7.76 5.99 1.77 29.5% Earnings per share pre (€)2 5.10 5.92 – 0.82 – 13.9% Business free cash flow2 2,508 3,193 – 685 – 21.4% 1 Fiscal 2017 has been adjusted, see Note (49) “Effects from new accounting standards and other presentation and measurement changes” in the Notes to the Consolidated Financial Statements. 2 Not defined by International Financial Reporting Standard IFRS( s). MERCK GROUP MERCK GROUP Net sales EBITDA pre2 € million € million 20181 14,836 20181 3,800 20171 14,517 20171 4,246 2016 15,024 2016 4,490 2015 12,845 2015 3,630 2014 11,363 2014 3,388 1 Excluding the Consumer Health business divested in fiscal 2018. 2 Not defined by International Financial Reporting Standards IFRS( s). Key figure for fiscal 2017 adjusted. Business Sectors Healthcare Life Science Performance Materials 4 HIGHLIGHTS OF 2018 HIGHLIGHTS OF 2018 Highlights of 2018 February 21 Life Science enhances presence in Asia In 2018, we invested in a cell culture facility in South Korea, a manufacturing and distribution center in India, and a facility to accelerate Mobius® single-use manufacturing in China. With these new locations, an investment of € 40 mil- lion, we are responding to growing demand from the biotech industry in Asia. April 19 Merck sells Consumer Health We reached an agreement to sell our Con- sumer Health business to Procter & Gamble for a cash purchase price of approximately € 3.4 billion. Consumer Health transferred to P&G on December 1. This is a further step in our strategic orientation toward innovation-driven businesses. May 3 350 years of Merck This year offered a good reason to celebrate in Darmstadt together with 900 guests from politics, business and industry. During this an- niversary year, we looked to the future as well as the past. For instance, we opened a new innovation center in Darmstadt that pro- vides more space for smart projects outside 350 of our existing business areas. Throughout 2018, we also held a number of other anniver- years of Merck sary events around the world. HIGHLIGHTS OF 2018 HIGHLIGHTS OF 2018 5 June 20 Partnership to accelerate our CRISPR initiative We announced a partnership with Tongji University in Shanghai. As a member of our CRISPR Core Partnership Program, we will 中国 provide the university exclusive access to our genome-editing technology and comprehensive technical support. June 20 Merck forms cooperation with Alibaba Health To significantly improve the lives of 40 million patients in China by 2025 is an ambitious goal. We have teamed up with Internet healthcare company Alibaba Health to meet this challenge. The collaboration aims to provide Chinese patients with improved access to healthcare ser- vices via a health platform that will start out by tracking drugs for patients with diabetes, thy- roid disorders and cardiovascular diseases. June 20 New OLED technology center in Shanghai We are complementing our OLED positions in Asia with a new OLED technology center in Shanghai – in addition to the existing ones in Korea and Taiwan. Working as a local partner with our customers, we intend to drive inno- vations forward for the display industry and bring them to market faster. 6 HIGHLIGHTS OF 2018 HIGHLIGHTS OF 2018 July 3 Transformation program for Performance Materials To secure the future prospects of Performance Materials, we have launched the transfor- mation program Bright Future with the aim of further expanding our position as a leading supplier of solutions for the electronics indus- try. After 2019, the average annual sales growth of Performance Materials is expected to be between 2% and 3% again, with Semiconductor Solutions as a significant driver of this growth. July 17 Research heroes wanted We are launching the “Future Insight Prize”, with an award of up to € 1 million annually for groundbreaking scientific work. Over the next 35 years, we’ll be awarding it to pro - mote innovations in the areas of health, nutri- tion and energy. July 30 FDA agrees to review request for approval of cladribine tablets The U.S. Food and Drug Administration (FDA) accepted for filing the New Drug Application for cladribine tablets as a potential treatment for patients with relapsing forms of multiple sclerosis. The FDA is examining whether cladribine tablets, a short-course oral treatment, can be used to treat patients in the United States. The proposed dosing is a maximum of 20 days of treatment over two years. HIGHLIGHTS OF 2018 HIGHLIGHTS OF 2018 7 September 11 Bavencio® in combination with INLY TA ® to combat kidney cancer The phase III JAVELIN Renal 101 study evaluat- ing Bavencio® and Pfizer’s Inlyta® compared with Sutent® as initial therapy for patients with advanced renal cell carcinoma yielded posi- tive top-line results. In February 2019 the FDA granted priority review to this therapy based on these interim results. October 17 From Darmstadt to 90 countries Since October 17, 2018, eight fully automated packaging lines and robotized logistics are up and running in the new packaging center, which covers a total area of 15,000 square meters. Here, medications from our current product portfolio are packaged and shipped to more than 90 countries. The new capacities help address rising patient demand for our primary products Glucophage®, Concor® and Euthyrox® in the therapeutic areas diabetes, cardiovascular diseases and thyroid disorders. Some € 63 million were invested in the con- struction of the new packaging center between 2015 and 2018. November 12 New innovation hub in Southern China We announced the plans to establish a new competence center for innovation in Guangzhou in Southern China scheduled to open September 2019. It will be located in the heart of a large biotechnology park where startups will conduct research in all three of our business sectors. To coincide with this, we will also start our three-month China Accelerator Program in 2019. 8 HIGHLIGHTS OF 2018 TABLE OF CONTENTS MAGAZINE November 19 Collaborate against cancer with Syntropy We want to advance cancer research. To that end, we intend to form a joint venture under the name Syntropy with software company Palantir Technologies. Syntropy will enable research cen- ters to have access to a collaborative techno l- ogy platform to drive forward cancer research, speed up scientific progress and improve peo- ple’s lives. November 20 Fourth place in the Access to Medicine Index This result means that we have maintained our ranking since the index was last published in 2016. We are proud of our efforts to improve access to medicine and thus the health of underserved populations. November 28 Recognized compensation system The European investors federation Better Finance recognized us as the company with the most shareholder-friendly board com- pensation system in the German DAX 30 stock index. We revised this system in the run-up to the 2018 Annual General Meeting. The estab- lishment of objective compensation criteria resulted in improved comprehensibility – now even with a seal of quality. HIGHLIGHTS OF 2018 TABLE OF CONTENTS MAGAZINE 9 Table of Contents Magazine 1. Heartbeats Why science? What fascinates us about it? We wanted to find out – so we followed the passion. Research drives us all 12–17 2. Vibrant China China is on the way to becoming a leading high-tech nation. We intend to take an active role in shaping this transformation with our China strategy. Big plans for China 20–22 The health platform for everyone 22–23 New partner 24–25 Semiconductors as a new driver of growth 26–27 3. Beyond tomorrow Can pandemics be predicted? How does smartphone glucose monitoring work? Where will our meat come from in the future? How can we better connect re­­searchers with each other? Whoever wants to actively shape the future, needs to ask the right questions. The needle-free sensor 30–31 A platform for the fight against cancer 32–33 Real meat without the side effects 34–35 New heroes wanted 36–37 10 HEARTBEATS HEARTBEATS 1 HEARTBEATS HEARTBEATS 11 Heart beats Why science? What fascinates us about it? Each of us has an answer to that. We wanted to find out what they were – so we followed the passion. 12 HEARTBEATS Research drives us all HEARTBEATS Research drives us all ANA LUISA CADORE Sales Expert, Life Science, São Paulo, Brazil MARC FEIGLIN Head of Alliance Management & Partnership, Yavne, Israel SHINJI OKITSU Group Leader Immunology, Healthcare, Billerica, United States FRANZISKA HÖLY Deputy Foreman, Performance Materials, Darmstadt, Germany SUNNY CHOI Talent and Development Manager, Seoul, Korea Get to know our Merck team from around the world at https://www.merckgroup.com/en/ annualreport/2018/magazine/heartbeats Research drives us all HEARTBEATS 13 “ It’s my job to give people the courage to explore new things that did not exist before.
Load more

Recommended publications
  • Fahrplanheft Muenster 2019
    Fahrplan Münster (Hessen) Gültig ab 9. Dezember 2018 2019 Ein kostenloser Service der RMV-Servicetelefon RMV-Mobilitätszentralen www.rmv.de 069 / 24 24 80 24 Kundenservice Benutzerhinweise DADINA, Europaplatz 1, 64293 Darmstadt Verkehrsbeschränkungen Ferien in Hessen (0 61 51) 3 60 51-0 S = nur an Schultagen 24.12.2018 - 12.1.2019 Mo.–Fr. 8–12.30 Uhr und Mo.–Do. 13–15.30 Uhr F = nicht an Schultagen 15.4.2019 - 27.4.2019 (0 61 51) 3 60 51-22 1.7.2019 - 9.8.2019 @ [email protected] www.dadina.de 30.9.2019 - 12.10.2019 RMV-Mobilitätszentrale Darmstadt | HEAG mobilo Kundenzentrum Zug, Bus oder Straßenbahn? Am Hauptbahnhof 20 a, Darmstadt | Luisenplatz 6, Darmstadt a Zugfahrten b S-Bahn-Fahrten (0 61 51) 3 60 51-51 | (0 61 51) 7 09-41 15 d Busfahrten e Straßenbahnfahrten Öffnungszeiten: Mo.–Fr. 8–18 Uhr und Sa. 9–16 | 13 Uhr An Silvester (31.12.), an Fastnacht (1.3. - 5.3.2019), am Schloss- Fahrplanauskünfte grabenfest (30.5. - 2.6.2019) und am Heinerfest (4.7. - 8.7.2019) wird RMV-Servicetelefon (täglich 24 Stunden) (0 69) 24 24 80 24 auf verschiedenen Linien Sonderverkehr gefahren. Entsprechende RMV-Mobilitätszentrale (0 61 51) 3 60 51-51 Fahrpläne werden zeitnah unter www.dadina.de eingestellt. NightLiner DADINA (0 61 51) 3 60 51-0 verkehren auch am 25.12.2018, am 3.3., 4.3., 5.3., 18.4., 19.4., 21.4., HEAG mobilo (0 61 51) 7 09-40 00 30.4., 29.5., 9.6., 19.6.
    [Show full text]
  • Biomarin Pharmaceutical Inc
    BIOMARIN PHARMACEUTICAL INC FORM 10-K (Annual Report) Filed 03/02/15 for the Period Ending 12/31/14 Address 105 DIGITAL DRIVE NOVATO, CA 94949 Telephone 4155066700 CIK 0001048477 Symbol BMRN SIC Code 2834 - Pharmaceutical Preparations Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/31 http://www.edgar-online.com © Copyright 2015, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 Or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-26727 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 68 -0397820 (State of other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 770 Lindaro Street San Rafael, California 94901 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (415) 506-6700 Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange on Which Registered Common Stock, $.001 par value The NASDAQ Global Select Market Securities registered under Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
    [Show full text]
  • Q2 2010 Half-Year Financial Report Worldreginfo - C49e8129-Cd51-43E5-Af66-E15ec3c851f8 2
    Q2 2010 Half-Year Financial Report WorldReginfo - c49e8129-cd51-43e5-af66-e15ec3c851f8 2 CONTENTS 3 Half-Year Management Report of the Merck Group as of June 30, 2010 3 At a glance | Highlights 4 Merck Group 8 Merck shares 9 Business sectors 11 Divisions 11 Merck Serono 13 Consumer Health Care 15 Liquid Crystals 16 Performance & Life Science Chemicals 17 Merck Millipore 18 Corporate and Other 18 Risk Report 19 Report on Expected Developments 20 Half-Year Consolidated Financial Statements as of June 30, 2010 31 Responsibility Statement 32 Executive Board | Supervisory Board | Capital structure 33 Financial calendar for 2010 | Publication contributors Cover photo: Automated distribution of miniscule particles onto microtiter plates. These are used to synthesize compound libraries for ultra-high-throughput screening in drug discovery research. WorldReginfo - c49e8129-cd51-43e5-af66-e15ec3c851f8 Half-Year Management Report of the Merck Group as of June 30, 2010 3 At a glance | Highlights AT A glaNCE Key figures – 2nd quarter 2010 Pharma­ Corporate Change EUR million ceuticals Chemicals and Other Total in % Total revenues 1,564.4 643.6 – 2,208.0 15.6 Gross margin 1,297.2 393.5 – 1,690.8 21.5 Research and development –302.2 –36.5 –0.1 –338.8 –0.5 Operating result 158.2 166.0 2.0 326.2 76.8 Exceptional items – – –1.2 –1.2 – Earnings before interest and tax (EBIT) 158.2 166.0 0.8 325.0 76.2 EBIT before depreciation and amortization (EBITDA) 350.0 208.6 1.3 559.9 38.4 Return on sales in % (ROS: operating result/total revenues) 10.1 25.8 – 14.8
    [Show full text]
  • (190902 Sortierung Landkreise Übersicht Starke
    Starke Heimat Hessen - Landkreise 1 2 3 4 5 6 7 8 (Summe von 2-7) Belastung - Abschöpfung Verbesserung gegenüber Rechnerischer Heimatumlage (75 %) Zuwachs bei den 2019 (Vollabschöpfung der Zuwachs der Erhöhungsbetrag für Fördermittel GKZ Kommunen zugunsten der kommunalen Schlüsselzuweisungen im KFA Digitalisierung der Kommunen Krankenhäuser** erhöhten Gewerbesteuereinnahmen Kindertageseinrichtungen Verwaltungskräfte Schule Familie (Hochrechnung * Gewerbesteuerumlage (120,7 Mio. Euro) gesamt 400 Mio. Euro) zugunsten des Landes) kreisfreie Städte 06411000 DARMSTADT, WISSENSCHAFTSSTADT 8.133.471 2.711.157 2.700.661 3.593.170 168.157 255.906 1.778.992 11.208.044 06412000 FRANKFURT AM MAIN, STADT 97.701.288 32.567.096 869.101 22.911.450 602.671 413.119 4.048.110 61.411.547 06413000 OFFENBACH AM MAIN, STADT 5.080.531 1.693.510 4.405.825 2.667.185 117.876 263.966 1.387.056 10.535.418 06414000 WIESBADEN, LANDESHAUPTSTADT 16.408.810 5.469.603 4.430.367 7.500.421 250.825 444.510 2.327.691 20.423.417 06611000 KASSEL, DOCUMENTA-STADT 9.157.158 3.052.386 5.148.458 3.872.262 197.630 381.823 2.897.614 15.550.172 Summe 136.481.258 45.493.753 17.554.411 40.544.488 1.337.158 1.759.324 12.439.464 119.128.598 Landkreis Bergstraße 06431000 LANDKREIS BERGSTRASSE - - 1.935.474 - 188.212 209.372 - 2.333.057 06431001 ABTSTEINACH 80.681 26.894 7.889 36.326 - 7.500 - 78.609 06431002 BENSHEIM, STADT 2.809.122 936.374 - 720.981 - 46.591 141.407 1.845.354 06431003 BIBLIS 101.731 33.910 55.009 130.240 - 16.298 - 235.457 06431004 BIRKENAU 141.688 47.229 102.655 154.496
    [Show full text]
  • Unity: Concern Over Patent Licensing Draft .•.....• 1 Proposal on Cancelling Door-To-Door Sales Deals •....•
    • Issue No. 421 Report No. 311, February 11, 1977 IN THIS ISSUE page Connnunity: Concern over Patent Licensing Draft .•.....• 1 Proposal on Cancelling Door-to-Door Sales Deals •....•. 2 Briefs: Court of Auditors; Fishing Licenses .•...•....• 3 Italy: 'Social Pact' Skirts Wage Cost Issue •........•. 3 Ireland: Budget Raises Speculation on Elections ....... 4 Britain: Modest Upturn Inspires Hopes, Caution ........ S France: Employers Want Shift in Social Cost Burden ..•. 6 Germany: Labor Costs Now Higher Than in USA .•.•••••••• 7 Euro Company Scene •••......•.....•.••..•.•..•....•. , •. 7 &unity: The European Connnission is going to great lengths to alle­ Business Fears viate the concern of the European business connnunity, es­ over Patent pecially in Germany and the U.K., over a preliminary draft Licensing Draft regulation that would exempt en bloc from the Article 85(1) ban any licensing agreements containing certain restrictive clauses. The Connnission and national experts were sched­ uled to discuss the document again this month, before in­ viting connnents from national business associations. In the meantime, however, Brussels has been taken by surprise by the publication of the confidential preliminary draft in a respected German financial newspaper. Connnission offi­ cials are now trying to counter criticism of business rep­ resentatives, who have described the draft as being "too narrowly conceived, contradictory, and impractical." The regulation would relieve the parties both from no­ tifying the Connnission and from applying for an exemption for a restrictive licensing agreement (as they are required to do now) if the latter meets the criteria set out in the draft regulation. A block exemption would greatly ease the Connnission's work load because the applications for exemp­ tions have been piling up by the tens of thousands.
    [Show full text]
  • Eppertshausen
    Partner Abfallkalender www.da-di-werk.de www.zaw-online.de ZAW Abfall-App Eppertshausen www.azurgmbh.de 2021Biotonne JANUAR FEBRUAR MÄRZ APRIL MAI JUNI 5 9 1 Fr Neujahr 1 Mo 1 Mo 1 Do 1 Sa Maifeiertag 1 Di Altpapiertonne & -container 2 Sa 2 Di 2 Di 2 Fr Karfreitag 2 So 2 Mi 18 3 So 3 Mi 3 Mi 3 Sa 3 Mo 3 Do Fronleichnam 1 Restmülltonne & -container 4 Mo 4 Do 4 Do 4 So Ostersonntag 4 Di 4 Fr 14 5 Di 5 Fr 5 Fr 5 Mo Ostermontag 5 Mi 5 Sa Restmüllcontainer – 6 Mi 6 Sa 6 Sa 6 Di 6 Do 6 So nur wöchentliche Leerung 23 7 Do 7 So 7 So 7 Mi 7 Fr 7 Mo 6 10 Gelbe Säcke 8 Fr 8 Mo 8 Mo 8 Do 8 Sa 8 Di 9 Sa 9 Di 9 Di 9 Fr 9 So 9 Mi 10 So 10 Mi 10 Mi 10 Sa 10 Mo 10 Do 2 19 11 Mo 11 Do 11 Do 11 So 11 Di 11 Fr Reklamationen zur Abfuhr 15 Bio Papier Restmüll Sperrmüll 12 Di 12 Fr 12 Fr 12 Mo 12 Mi 12 Sa Reso GmbH 13 Mi 13 Sa 13 Sa 13 Di 13 Do Christi Himmelfahrt 13 So Hotline: 06159 7175930 24 E-Mail: [email protected] 14 Do 14 So 14 So 14 Mi 14 Fr 14 Mo Nur Gelber Sack-Reklamationen 7 11 15 Fr 15 Mo 15 Mo 15 Do 15 Sa 15 Di REMONDIS GmbH & Co.
    [Show full text]
  • The Resiliency Compass: Navigating Global Value Chain Disruption in an Age of Uncertainty
    In Collaboration with Kearney The Resiliency Compass: Navigating Global Value Chain Disruption in an Age of Uncertainty WHITE PAPER JULY 2021 Images: Getty Images, Unsplash Contents Foreword 3 Executive summary 4 1 Disruption drives a rethink 5 2 Resilience in action 8 2.1 Getting to grips with disruption 8 2.2 Introducing the resiliency compass 8 2.3 Who are the resilience leaders? 10 3 Setting the right course with the resiliency compass 11 4 Call for action: global coordination for the long term 14 Methodology 15 Contributors 16 Acknowledgements 17 Endnotes 19 © 2021 World Economic Forum. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, including photocopying and recording, or by any information storage and retrieval system. The Resiliency Compass: Navigating Global Value Chain Disruption in an Age of Uncertainty 2 July 2021 The Resiliency Compass: Navigating Global Value Chain Disruption in an Age of Uncertainty Foreword Unlocking the future of cooperation, resilience and prosperity for global value chains. Francisco Betti Per Kristian Hong Head of Shaping the Future of Managing Director and Advanced Manufacturing and Partner, Strategic Operations Production, Member of the and World Economic Forum Executive Committee, World Relationship Lead, Kearney Economic Forum COVID-19 has kept manufacturing companies systems if both the global economy and companies beyond busy for many months and the challenges are to successfully navigate future disruptions that are far from over, from ensuring safety and may affect global value chains. security on the shop floor and facing supply and demand disruptions to accelerating digital In 2020, the World Economic Forum, in transformation and reskilling to build resilience.
    [Show full text]
  • Kommunale Steuern Im Landkreis Darmstadt
    Bund der Steuerzahler Hessen e.V. Mai 2019 Kommunale Steuern im Landkreis Darmstadt - Dieburg im Jahr 2019 Hebesatz in Prozent (Veränderung zu 2018) Grundsteuer Hundesteuer Spiel- Straßenbeiträge Defizitärer Haushalt Gewerbe- Pferde- Vergnügungs- Kulturförder- Wettauf- Zweitwoh- Verabschie- Stadt/Gemeinde Für gefährliche apparate- wiederkeh- steuer 1. Hund steuer steuer abgabe wandsteuer nungsteuer einmalig 2018 2019 dung A B Hunde steuer rend Alsbach-Hähnlein 380 365 365 60,00 360,00 nein ja nein nein nein ja [10%] ja nein ja ja ja Babenhausen 390 370 495 60,00 nein nein ja nein nein nein ja [10%] nein ja nein nein ja Bickenbach 400(+20) 400(+65) 425(+95) 40,00 500,00 nein ja nein nein nein nein ja nein ja ja ja Dieburg 380 450 450 54,00 504,00 nein ja nein nein nein nein nein nein nein nein ja Eppertshausen 350 0 365(+45) 48,00 600,00 nein ja nein nein nein nein ja nein ja ja ja Erzhausen 380 300 450 48,00 600,00 nein ja nein nein nein nein nein nein nein nein ja Fischbachtal 380 340 390 48,00 600,00 nein ja nein nein nein nein ja nein nein nein ja Griesheim 390 595 595 54,00 nein nein ja nein nein nein nein nein ja nein nein ja Groß-Bieberau 385 350 490 48,00 600,00 nein ja nein nein nein nein nein ja ja nein ja Groß-Umstadt 380 340 525 42,00 504,00 nein ja nein nein ja nein nein nein nein nein ja Groß-Zimmern 380 350 350 48,00 600,00 nein ja nein nein nein nein ja nein* nein nein ja Messel 380 390 507(+87) 54,00 600,00 nein ja nein nein nein nein nein ja nein nein ja Modautal 380 400 400 60,00 600,00 nein nein nein nein nein ja [10%]
    [Show full text]
  • Disclaimerthis Is a Publication of a Third Party
    DisclaimerThis is a publication of a third party. Merck KGaA, Darmstadt, Germany is not responsible for its content. Whenever this document refers to Merck it refers to Merck KGaA, Darmstadt, Germany or the group of companies affiliated with Merck KGaA, Darmstadt, Germany. In the United States and Canada the group of companies affiliated with Merck KGaA, Darmstadt, Germany operates under individual business names (EMD Serono, MilliporeSigma, EMD Performance Materials). 2 November 2018 Corporates Merck KGaA Merck KGaAGermany, Chemicals/Pharmaceuticals STABLE Germany, Chemicals/Pharmaceuticals A- Corporate profile Ratings & Outlook Merck KGaA is a diversified chemicals/pharmaceuticals group that was founded in 1668 Corporate Ratings A-/Stable with the opening of a Merck pharmacy in Darmstadt, Germany, where the group is still Short Term Rating S-1/Stable based. The Merck family holds 70% of the voting rights with the remainder in public ownership. After several acquisitions and divestments, the group now consists of three divisions: healthcare (pharmaceuticals and consumer healthcare), life science and Analysts performance materials (centred on its global market leadership in liquid crystals). In 2015, Olaf Tölke Merck acquired the US-based life science company Sigma Aldrich for a price of +49 69 6677389 11 USD 17bn and became one of the consolidators in that industry. In pharmaceuticals, it is [email protected] a specialised, mid-sized producer of drugs, relying on two blockbuster products, Erbitux and Rebif, but has developed a new focus on immuno-oncological products, mainly Related methodology represented by its antibody avelumab. At the end of 2014, US-based big pharma Corporate Rating Methodology, company Pfizer acquired partial ownership of the molecule as well as US distribution January 2018 rights for USD 850m.
    [Show full text]
  • Reducing Prescription Drug Costs in Colorado Cost Drivers and Strategies to Address Them
    2nd Edition Reducing Prescription Drug Costs in Colorado Cost Drivers and Strategies to Address Them January 2021 Contents Forward to Reducing Prescription Drug Costs in Colorado, 2nd Edition ........... 4 2020 Updates to This Report .................................................................. 4 Executive Summary ............................................................................ 6 Introduction and Purpose ...................................................................... 6 Cost Drivers ...................................................................................... 7 Prioritized Solutions ............................................................................ 8 Learning from Medicaid Policy ............................................................... 12 The Department Invites Your Collaborative Partnership .................................. 12 Industry Trends and Background Information ............................................. 13 Prescription Drug Cost, Utilization, and Trends ........................................... 13 The U.S. Pays the Highest Prices for Pharmaceutical Drugs in the World .............. 16 Many Coloradans Aren’t Taking Their Drugs Appropriately Because They Can’t Afford Them, Often Leading to Worse Health Outcomes That Are More Costly ....... 16 Major Drivers of Prescription Drug Prices .................................................. 18 Patent Protections .............................................................................. 18 Anti-Competitive Practices and Price Fixing
    [Show full text]
  • 1. Pressemitteilung Verkehrsgipfel
    Verkehrsgipfel verabschiedet Bausteine für eine gemeinsame Verkehrswende in der Region Darmstadt Ende Juni 2019 hat die DADINA-Verbandsversammlung den Vorstand beauftragt, zusammen mit dem Landkreis Darmstadt-Dieburg und der Stadt Darmstadt im Herbst zu einem regionalen Verkehrsgipfel unter Beteiligung der Fachämter, der Verkehrsunternehmen sowie der Vorsitzenden der DADINA-Gremien einzuladen. Ziel sollte die regionale Stärkung des öffentlichen Personennahverkehrs insbesondere in der Verbindung von Darmstadt zum östlichen Teil des Landkreises Darmstadt-Dieburg sein. Ablauf des Verkehrsgipfels Im Dezember 2019 fand der mehrstündige Verkehrsgipfel in Darmstadt statt. Teilnehmer waren Oberbürgermeister Partsch, Landrat Schellhaas, Erster Kreisbeigeordneter Ahrnt, Herr Busch (RMV), Herr Kalbfuss (HEAG mobilo), Bürgermeisterin Sprößler (Vorsitzende Bürgermeisterdienstversammlung), Herr Ludwig (Vorsitzender DADINA- Verbandsversammlung), Bürgermeister Buchwald (Vorsitzender Städte- und Gemeindebeirat), Frau Metzker (Mobilitätsamt Darmstadt), Herr Kolmer (Amt für Wirtschaft und Stadtentwicklung Darmstadt), Herr Rohrmann (DADINA-Fahrgastbeirat) und Herr Altenhein (DADINA). Nach den einführenden Worten der beiden DADINA-Vorsitzenden Ahrnt und Partsch stellte DADINA-Geschäftsführer Altenhein kurz die vorliegenden Gutachten und Vorschläge insbesondere zur Verbindung zwischen der Stadt Darmstadt und dem östlichen Teil des Landkreises vor. Anschließend referierte Thomas Busch vom RMV über die Planungen des RMV für die Eisenbahnstrecken in der Region.
    [Show full text]
  • Stand: November 2020
    Stand: November 2020 Antragstellende beteiligte Bewillligung # Gemeinde / Kreis Aufgabenbereich Gemeinden vom Gemeindegruppe 1 Weiterstadt Darmstadt-Dieburg Erzhausen Standesamtsbezirk 25.09.2008 Beerfelden Hesseneck Haushalts- und 2 Mossautal Odenwald 25.09.2008 Rothenberg Rechnungswesen Sensbachtal Hünstetten Rheingau-Taunus- 3 Idstein Niedernhausen Standesamtsbezirk 26.11.2008 Kreis Waldems 4 Wahlsburg Kassel Oberweser Bauhof 11.03.2010 5 Groß-Umstadt Darmstadt-Dieburg Otzberg Errichtung eines Recyclinghofes 14.01.2009 Gemeinsames Beratungs- und Dienstleistungszentrum im Rheingau-Taunus- Rahmen der 6 Taunusstein 10 Gemeinden 02.09.2009 Kreis Haushaltswirtschaft auf der Grundlage der doppelten Buchführung Prüfung der elektrischen 7 Fuldatal Kassel 10 Gemeinden 26.11.2008 Anlagen und Betriebsmittel Sicherstellung des 8 Bischoffen Lahn-Dill-Kreis Hohenahr abwehrenden Brandschutzes 27.01.2009 und der allg. Hilfe 9 Kelkheim Main-Taunus-Kreis Eppstein Standesamtsbezirk 24.02.2009 Standesamtswesen, Kindergartenverwaltung, 10 Ebersburg Fulda Gersfeld 02.07.2009 Senioren- betreuung Fischbachtal 11 Reinheim Darmstadt-Dieburg Groß-Bieberau Werkstoffannahme 22.12.2009 Ober-Ramstadt 12 Mücke Vogelsbergkreis Gemünden Standesamtsbezirk 27.04.2009 (Felda) 13 Seligenstadt Offenbach Mainhausen Gemeinsames Personalamt 04.05.2009 Marburg- Cölbe 14 Wetter (Hessen) kommunale Jugendpflege 06.09.2009 Biedenkopf Lahntal Münchhausen Waldeck- Gemeinsame Steuer- und 15 Bromskirchen Allendorf (Eder) 27.04.2009 Frankenberg Personalverwaltung Antragstellende beteiligte
    [Show full text]